MediSense preparing for Precision QID glucose monitor launch in U.S..
This article was originally published in The Gray Sheet
Executive SummaryMEDISENSE PRECISION QID THIRD GENERATION GLUCOSE MONITORING SYSTEM will begin U.S. shipments "at or around the end of this quarter," MediSense Chairman and CEO Robert Coleman, PhD, said at a May 16 session of the Alex. Brown & Sons health care seminar in Baltimore. Both the home glucose monitoring device and attendant disposable strips were cleared by FDA on March 23.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.